HER3 and mutant EGFR meet MET

被引：64

作者：

Arteaga, Carlos L. ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Breast Canc Res Program, Nashville, TN 37232 USA

来源：

NATURE MEDICINE | 2007年 / 13卷 / 06期

关键词：

D O I：

10.1038/nm0607-675

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.

引用

页码：675 / 677

页数：3

共 13 条

[1] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[2] Opinion -: Invasive growth:: a MET-driven genetic programme for cancer and stem cells [J].

Boccaccio, Carla ;

Comoglio, Paolo M. .

NATURE REVIEWS CANCER, 2006, 6 (08) :637-645

[3] Strategies to overcome resistance to targeted protein kinase inhibitors [J].

Daub, H ;

Specht, K ;

Ullrich, A .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1001-1010

[4] ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines [J].

Engelman, JA ;

Jänne, PA ;

Mermel, C ;

Pearlberg, J ;

Mukohara, T ;

Fleet, C ;

Cichowski, K ;

Johnson, BE ;

Cantley, LC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3788-3793

[5]

ENGELMAN JA, 2007, SCIENCE

[6] Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer [J].

Engelman, Jeffrey A. ;

Mukohara, Toru ;

Zejnullahu, Kreshnik ;

Lifshits, Eugene ;

Borras, Ana M. ;

Gale, Christopher-Michael ;

Naumov, George N. ;

Yeap, Beow Y. ;

Jarrell, Emily ;

Sun, Jason ;

Tracy, Sean ;

Zhao, Xiaojun ;

Heymach, John V. ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (10) :2695-2706

[7] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[8] Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib [J].

Kosaka, Takayuki ;

Yatabe, Yasushi ;

Endoh, Hideki ;

Yoshida, Kimihide ;

Hida, Toyoaki ;

Tsuboi, Masahiro ;

Tada, Hirohito ;

Kuwano, Hiroyuki ;

Mitsudomi, Tetsuya .

CLINICAL CANCER RESEARCH, 2006, 12 (19) :5764-5769

[9] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].

Pao, W ;

Miller, VA ;

Politi, KA ;

Riely, GJ ;

Somwar, R ;

Zakowski, MF ;

Kris, MG ;

Varmus, H .

PLOS MEDICINE, 2005, 2 (03) :225-235

[10]

Ricci C, 2002, CANCER RES, V62, P5995

← 1 2 →